StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Trading Up 8.3 %
Shares of CYCC opened at $1.43 on Tuesday. The firm has a market capitalization of $3.07 million, a price-to-earnings ratio of -0.09 and a beta of 0.51. The firm’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.58. Cyclacel Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $10.12.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the prior year, the company posted ($6.60) EPS. On average, analysts predict that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
See Also
- Five stocks we like better than Cyclacel Pharmaceuticals
- How to Choose Top Rated Stocks
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- The Significance of Brokerage Rankings in Stock Selection
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are the U.K. Market Holidays? How to Invest and Trade
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.